Loading organizations...
§ Private Profile · Newton, MA 02467, USA
Biotech company developing biomimetic accommodating intraocular lenses for cataract patients, restoring full range vision.
Based in Chestnut Hill, Massachusetts, Adaptilens is a preclinical medical device company developing biomimetic accommodating intraocular lenses for cataract surgery that mimic the natural human eye to restore near, intermediate, and distance vision. By allowing the ciliary muscles to adjust focus naturally, this proprietary technology aims to eliminate the need for corrective eyeglasses following surgical procedures. The biotechnology firm has raised over twenty million dollars in total funding, highlighted by a large Series A financing round led by Perceptive Xontogeny Venture Funds and a seed round backed by Pillar VC and Accanto Partners. With incubation support from the Harvard Innovation Labs, the startup is currently advancing its two filed patents and proprietary product toward initial human clinical trials projected for late 2025. Doctor Liane Clamen officially founded the enterprise in 2020 to help patients seeking restored youthful vision.
Adaptilens has raised $20.0M across 2 funding rounds.
Adaptilens has raised $20.0M in total across 2 funding rounds.
Adaptilens has raised $20.0M across 2 funding rounds. Most recently, it raised $18.0M Series A in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $18M Series A | Gianna Hoffman Luca | Founder Collective, Pillar VC, Adam Gries, 380 CAP, Accanto Partners | Announced |
| Nov 1, 2020 | $2M Seed | Pillar VC | Founder Collective, Adam Gries, Dick Costolo, Matthew Dellavedova, Michael Arrington, Accanto Partners | Announced |
Adaptilens is a medtech startup founded in 2020 that develops the Accommodating Intraocular Lens (A-IOL), a biomimetic lens designed to restore the full range of near, intermediate, and distance vision for cataract patients by mimicking the natural flexibility of a young, healthy human lens.[1][3][6] It serves primarily patients undergoing cataract surgery—expected to affect 50 million Americans by 2050—and addresses limitations of traditional monofocal IOLs, which often require glasses post-surgery and cause side effects like halos or glare.[2][6] The company has raised $20.87M total, including a $17.5M Series A led by PXV Funds just 25 days ago, fueling progression from pre-clinical to first-in-human trials.[1][2]
This funding builds on a $1.6M seed round and grants like Harvard’s President’s Innovation Challenge, signaling strong growth momentum as Adaptilens advances its patent-protected bottlebrush polymer (BBP) technology toward clinical validation.[1][4][5]
Adaptilens was founded in 2019 by Liane Clamen, MD, an ophthalmologist whose idea for a truly accommodating IOL emerged over 20 years earlier around 2002, inspired by the unmet need to replicate the youthful lens's flexibility lost in aging eyes.[4][5] Clamen, drawing from her clinical experience, partnered with experts including Duke University's Matt Becker, whose lab developed the novel BBP polymers enabling the lens to respond to ciliary muscles.[3][4]
Early traction came via accelerators like MassChallenge and Harvard Innovation Labs' Launch Lab X, where Adaptilens won $75K in the 2022 President’s Innovation Challenge for health sciences.[5] This led to seed funding from Pillar VC and Accanto Partners, followed by the pivotal Series A in 2024, marking the shift from prototype to clinical readiness.[1][5]
Adaptilens rides the aging population wave, where cataracts will double to 50 million U.S. cases by 2050 amid advances in polymer science and minimally invasive surgery.[1][6] Timing aligns with post-Harold Ridley IOL evolution—75+ years since 1949—now feasible via breakthroughs like Becker's polymers, enabling the "holy grail" of true accommodation.[3][4]
Market forces favor it: surging demand for premium IOLs (reducing glasses reliance), investor appetite for medtech (e.g., $17.5M Series A), and regulatory paths cleared by prior accommodating lens trials.[1][2] It influences ophthalmology by pushing biomimicry, potentially setting standards for vision restoration and inspiring similar nature-imitating implants in other fields.[3][5]
Adaptilens is poised for first-in-human trials in ~1.5 years, targeting market entry by 2031 with a working prototype, elite team, and fresh capital to scale manufacturing and commercialization.[1][4][5] Trends like personalized medtech, AI-optimized polymers, and value-based care for cataracts will accelerate adoption, especially as demographics strain healthcare.
Its influence could evolve from niche innovator to category leader, transforming post-cataract life for millions—validating Clamen's 20-year vision and proving biomimicry's power in restoring what nature perfected.[2][5]
Adaptilens has raised $20.0M in total across 2 funding rounds.
Adaptilens's investors include Gianna Hoffman-Luca, Founder Collective, Pillar VC, Adam Gries, 380 Cap, Accanto Partners, Dick Costolo, Matthew Dellavedova, Michael Arrington.